KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 109 filers reported holding KALA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.98 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $85,000 | -63.7% | 32,576 | -26.2% | 0.00% | -66.7% |
| Q2 2021 | $234,000 | -72.5% | 44,169 | -65.0% | 0.00% | -72.7% |
| Q1 2021 | $851,000 | -19.4% | 126,254 | -18.9% | 0.01% | -26.7% |
| Q4 2020 | $1,056,000 | +3306.5% | 155,768 | +5196.4% | 0.02% | +1400.0% |
| Q2 2020 | $31,000 | -42.6% | 2,941 | -73.4% | 0.00% | -66.7% |
| Q4 2018 | $54,000 | -76.3% | 11,037 | +10.6% | 0.00% | -76.9% |
| Q3 2017 | $228,000 | – | 9,978 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,142,360 | $7,745,000 | 4.83% |
| RA Capital Management | 10,874,613 | $73,730,000 | 1.03% |
| Mesirow Financial Investment Management, Inc. | 43,431 | $294,462,000 | 0.93% |
| Parkman Healthcare Partners LLC | 272,445 | $1,847,000 | 0.47% |
| Samsara BioCapital, LLC | 601,162 | $4,076,000 | 0.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $693,000 | 0.40% |
| Eventide Asset Management | 3,450,000 | $23,391,000 | 0.36% |
| Orbimed Advisors | 5,465,030 | $37,053,000 | 0.32% |
| Vivo Capital, LLC | 786,883 | $5,335,000 | 0.24% |
| Knights of Columbus Asset Advisors LLC | 169,429 | $1,149,000 | 0.12% |